{"id":65691,"date":"2026-05-19T22:31:07","date_gmt":"2026-05-19T14:31:07","guid":{"rendered":"https:\/\/flcube.com\/?p=65691"},"modified":"2026-05-19T22:31:07","modified_gmt":"2026-05-19T14:31:07","slug":"sanegene-bios-c3-targeted-sirna-sgb-9768-expands-to-hematological-disorders-following-nmpa-clinical-trial-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65691","title":{"rendered":"Sanegene Bio&#8217;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval"},"content":{"rendered":"\n<p><strong>Suzhou Sanegene Bio Inc.<\/strong>, an <strong>RNAi specialist<\/strong> with R&amp;D centers in the <strong>U.S. and China<\/strong>, announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for its investigational <strong>C3-targeted siRNA drug SGB-9768<\/strong> in <strong>complement-mediated hematological disorders<\/strong>. The approval enables clinical evaluation in <strong>paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> and <strong>atypical hemolytic uremic syndrome (aHUS)<\/strong>, expanding beyond its previously approved indications in <strong>complement-mediated kidney diseases<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-expansion-amp-indication-portfolio\">Regulatory Expansion &amp; Indication Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Previously Approved Indications<\/th><th>Newly Approved Indications<\/th><\/tr><\/thead><tbody><tr><td><strong>IgA nephropathy (IgAN)<\/strong><\/td><td><strong>Paroxysmal nocturnal hemoglobinuria (PNH)<\/strong><\/td><\/tr><tr><td><strong>C3 glomerulopathy (C3G)<\/strong><\/td><td><strong>Atypical hemolytic uremic syndrome (aHUS)<\/strong><\/td><\/tr><tr><td><strong>Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)<\/strong><\/td><td><strong>Additional complement-mediated hematological disorders<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>SGB-9768<\/strong> represents a <strong>novel therapeutic approach<\/strong> targeting the central complement pathway:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>C3-targeted small interfering RNA (siRNA)<\/strong> that silences C3 protein production at the mRNA level<\/li>\n\n\n\n<li><strong>Target Rationale<\/strong>: <strong>C3<\/strong> serves as the <strong>central convergence point<\/strong> of all complement activation pathways, making it an ideal target for broad complement inhibition<\/li>\n\n\n\n<li><strong>Administration<\/strong>: <strong>Subcutaneous delivery<\/strong> enabling convenient outpatient treatment<\/li>\n\n\n\n<li><strong>Therapeutic Advantage<\/strong>: Addresses root cause of complement dysregulation rather than downstream effects<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-i-clinical-data-amp-safety-profile\">Phase I Clinical Data &amp; Safety Profile<\/h2>\n\n\n\n<p>Completed <strong>Phase I trials<\/strong> demonstrated compelling proof-of-concept data:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy<\/strong>: <strong>Single subcutaneous dose<\/strong> achieved <strong>dose-dependent, robust, and durable reductions in C3 levels<\/strong><\/li>\n\n\n\n<li><strong>Pathway Inhibition<\/strong>: Demonstrated <strong>sustained inhibition of complement pathway activity<\/strong><\/li>\n\n\n\n<li><strong>Safety<\/strong>: <strong>Favorable safety and tolerability profile<\/strong> with no significant adverse events<\/li>\n\n\n\n<li><strong>Best-in-Class Potential<\/strong>: Duration and depth of C3 suppression position SGB-9768 as a <strong>potential best-in-class therapy<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-unmet-need\">Market Opportunity &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PNH Market<\/strong>: Global PNH therapeutics market valued at <strong>$3.5 billion annually<\/strong>, dominated by expensive monoclonal antibodies requiring frequent intravenous administration<\/li>\n\n\n\n<li><strong>aHUS Burden<\/strong>: Ultra-rare disease with limited treatment options and high morbidity despite existing complement inhibitors<\/li>\n\n\n\n<li><strong>Kidney Disease Expansion<\/strong>: IgAN alone affects <strong>1.5-2 million patients globally<\/strong>, representing substantial commercial opportunity<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: siRNA approach offers <strong>less frequent dosing<\/strong> and <strong>oral-like convenience<\/strong> compared to current IV\/SC biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-sanegene-bio\">Strategic Implications for Sanegene Bio<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Success across multiple complement-mediated diseases validates Sanegene&#8217;s <strong>RNAi platform capabilities<\/strong><\/li>\n\n\n\n<li><strong>Global Development Strategy<\/strong>: Dual U.S.-China R&amp;D presence enables <strong>parallel regulatory pathways<\/strong> in major markets<\/li>\n\n\n\n<li><strong>Portfolio Diversification<\/strong>: Expansion into both <strong>hematological and renal indications<\/strong> reduces single-indication risk<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Potential to capture significant share in <strong>high-value orphan disease markets<\/strong> with premium pricing<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Standards<\/strong>: Monoclonal antibodies (eculizumab, ravulizumab) dominate complement inhibition but require <strong>bi-weekly or monthly IV\/SC administration<\/strong><\/li>\n\n\n\n<li><strong>Differentiation Advantage<\/strong>: siRNA approach potentially enables <strong>quarterly or less frequent dosing<\/strong> with <strong>subcutaneous convenience<\/strong><\/li>\n\n\n\n<li><strong>Cost Structure<\/strong>: Manufacturing advantages of siRNA may enable <strong>competitive pricing<\/strong> while maintaining margins<\/li>\n\n\n\n<li><strong>First-Mover Potential<\/strong>: Among first siRNA therapies targeting C3 in clinical development for these indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-next-steps\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase II Initiation<\/strong>: Expected to begin <strong>Q3-Q4 2026<\/strong> in both hematological and renal indications<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong>: Parallel development in <strong>China (NMPA)<\/strong> and <strong>U.S. (FDA)<\/strong> leveraging dual R&amp;D infrastructure<\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Strong clinical data may attract <strong>strategic partnership interest<\/strong> from global pharmaceutical companies<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Orphan drug designations likely in both jurisdictions, providing <strong>market exclusivity<\/strong> and <strong>regulatory incentives<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for SGB-9768. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Sanegene Bio Inc., an RNAi specialist with R&amp;D centers in the U.S. and China,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,64,546],"class_list":["post-65691","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-rnai-aso","tag-sanegene-bio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanegene Bio&#039;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Sanegene Bio Inc., an RNAi specialist with R&amp;D centers in the U.S. and China, announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65691\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanegene Bio&#039;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval\" \/>\n<meta property=\"og:description\" content=\"Suzhou Sanegene Bio Inc., an RNAi specialist with R&amp;D centers in the U.S. and China, announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65691\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T14:31:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65691#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65691\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanegene Bio&#8217;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval\",\"datePublished\":\"2026-05-19T14:31:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65691\"},\"wordCount\":559,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"RNAi \\\/ ASO\",\"Sanegene Bio\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65691#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65691\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65691\",\"name\":\"Sanegene Bio's C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T14:31:07+00:00\",\"description\":\"Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China, announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65691#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65691\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65691#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanegene Bio&#8217;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanegene Bio's C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China, announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65691","og_locale":"en_US","og_type":"article","og_title":"Sanegene Bio's C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval","og_description":"Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China, announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.","og_url":"https:\/\/flcube.com\/?p=65691","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T14:31:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65691#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65691"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanegene Bio&#8217;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval","datePublished":"2026-05-19T14:31:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65691"},"wordCount":559,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","RNAi \/ ASO","Sanegene Bio"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65691#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65691","url":"https:\/\/flcube.com\/?p=65691","name":"Sanegene Bio's C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T14:31:07+00:00","description":"Suzhou Sanegene Bio Inc., an RNAi specialist with R&D centers in the U.S. and China, announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for its investigational C3-targeted siRNA drug SGB-9768 in complement-mediated hematological disorders. The approval enables clinical evaluation in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), expanding beyond its previously approved indications in complement-mediated kidney diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65691#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65691"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65691#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanegene Bio&#8217;s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65691"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65691\/revisions"}],"predecessor-version":[{"id":65692,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65691\/revisions\/65692"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}